Marcel Arias-Badia

523 total citations
12 papers, 362 citations indexed

About

Marcel Arias-Badia is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Marcel Arias-Badia has authored 12 papers receiving a total of 362 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Genetics. Recurrent topics in Marcel Arias-Badia's work include CAR-T cell therapy research (8 papers), Virus-based gene therapy research (6 papers) and Viral Infectious Diseases and Gene Expression in Insects (3 papers). Marcel Arias-Badia is often cited by papers focused on CAR-T cell therapy research (8 papers), Virus-based gene therapy research (6 papers) and Viral Infectious Diseases and Gene Expression in Insects (3 papers). Marcel Arias-Badia collaborates with scholars based in United States, Spain and South Africa. Marcel Arias-Badia's co-authors include Luis A. Rojas, Ramón Alemany, Rafael Moreno, Carlos Alberto Fajardo, Jana de Sostoa, Sònia Guedan, Carl H. June, Lawrence Fong, Gabriela N. Condezo and Carmen San Martı́n and has published in prestigious journals such as Nature, Immunity and Nature Immunology.

In The Last Decade

Marcel Arias-Badia

12 papers receiving 359 citations

Peers

Marcel Arias-Badia
Joachim Hagel United Kingdom
Hong-My Nguyen United States
Joshua D. Freedman United Kingdom
Sarah Knocke Germany
Michael Nemunaitis United States
Marcel Arias-Badia
Citations per year, relative to Marcel Arias-Badia Marcel Arias-Badia (= 1×) peers Dongling Gao

Countries citing papers authored by Marcel Arias-Badia

Since Specialization
Citations

This map shows the geographic impact of Marcel Arias-Badia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marcel Arias-Badia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marcel Arias-Badia more than expected).

Fields of papers citing papers by Marcel Arias-Badia

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marcel Arias-Badia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marcel Arias-Badia. The network helps show where Marcel Arias-Badia may publish in the future.

Co-authorship network of co-authors of Marcel Arias-Badia

This figure shows the co-authorship network connecting the top 25 collaborators of Marcel Arias-Badia. A scholar is included among the top collaborators of Marcel Arias-Badia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marcel Arias-Badia. Marcel Arias-Badia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Arias-Badia, Marcel, Peixi Chen, Aram Lyu, et al.. (2025). Sequential JAK inhibition enhances antitumor immunity after combined anti–PD-1 and anti-CTLA4. JCI Insight. 10(7). 2 indexed citations
2.
Arias-Badia, Marcel, Ryan Chang, & Lawrence Fong. (2024). γδ T cells as critical anti-tumor immune effectors. Nature Cancer. 5(8). 1145–1157. 17 indexed citations
3.
Lyu, Aram, Matthew Clark, Averey Lea, et al.. (2024). Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. Nature. 637(8048). 1207–1217. 44 indexed citations
4.
Arias-Badia, Marcel, Chien-Chun Steven Pai, Peixi Chen, et al.. (2024). E-cigarette exposure disrupts antitumor immunity and promotes metastasis. Frontiers in Immunology. 15. 1444020–1444020. 3 indexed citations
5.
Rancan, Chiara, Marcel Arias-Badia, Pranay Dogra, et al.. (2023). Exhausted intratumoral Vδ2− γδ T cells in human kidney cancer retain effector function. Nature Immunology. 24(4). 612–624. 44 indexed citations
6.
Arias-Badia, Marcel, Theresa A. Kadlecek, Neel H. Shah, et al.. (2023). TCR signaling promotes formation of an STS1-Cbl-b complex with pH-sensitive phosphatase activity that suppresses T cell function in acidic environments. Immunity. 56(12). 2682–2698.e9. 18 indexed citations
7.
Mato-Berciano, Ana, Sara Morgado, María Victoria Maliandi, et al.. (2021). Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11. Journal of Controlled Release. 332. 517–528. 22 indexed citations
8.
Moreno, Rafael, Carlos Alberto Fajardo, Marcel Arias-Badia, et al.. (2018). Evidence of Anti-tumoral Efficacy in an Immune Competent Setting with an iRGD-Modified Hyaluronidase-Armed Oncolytic Adenovirus. Molecular Therapy — Oncolytics. 8. 62–70. 15 indexed citations
9.
Fajardo, Carlos Alberto, Sònia Guedan, Luis A. Rojas, et al.. (2017). Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy. Cancer Research. 77(8). 2052–2063. 130 indexed citations
10.
Fajardo, Carlos Alberto, et al.. (2017). Arming oncolytic adenovirus with FAP-targeting bispecific T-cell engager to improve antitumor efficacy. Annals of Oncology. 28. xi18–xi18. 1 indexed citations
11.
Rojas, Luis A., Gabriela N. Condezo, Rafael Moreno, et al.. (2016). Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery. Journal of Controlled Release. 237. 78–88. 50 indexed citations
12.
Rodríguez-García, Alba, Erik Svensson, Carlos Alberto Fajardo, et al.. (2015). Insertion of exogenous epitopes in the E3-19K of oncolytic adenoviruses to enhance TAP-independent presentation and immunogenicity. Gene Therapy. 22(7). 596–601. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026